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development of retinopathy of prematurity (ROP). However, the results remain controversial. Therefore, the aim of the present
meta-analysis was to determine the association between VEGF-634G/C polymorphism and ROP risk.
Methods: Published literature from PubMed and other databases were retrieved. All studies evaluating the association between
VEGF-634G/C polymorphism and ROP risk were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated
using random or fixed effects model. A total of six case-control studies including 355 cases and 471 controls were included.
Results: By pooling all the studies, we found that VEGF-634G/C polymorphism was not associated with ROP risk at co-dominant
and allele levels and no association was also found in dominant and recessive models. While stratifying on ethnicity level no
association was observed in Caucasian and Asian population.
Discussion: This meta-analysis suggests that VEGF-634G/C polymorphism may not be associated with ROP risk, the association
between single VEGF-634G/C polymorphism and ROP risk awaits further investigation.
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Retinopathy of prematurity (ROP) is a developmental dis-
order that occurs in the incompletely vascularized retina of
premature infants and is an important cause of blindness
and impaired vision among children in both the developed
and the developing countries.1,2 Vision impairment induced
by ROP is an important problem, especially in middle-income
countries such as the European and Latin American countries.
In these regions, ROP is the most common cause of child-
hood blindness.3,4The pathogenesis of advanced ROP and its etiology is cur-
rently not known. In the past, many causative factors such as
length of time exposed to supplemental oxygen, excessive
light exposure, and hypoxia have been suggested, but evi-
dence for these as independent risk factors in recent years
is not compelling.5,6 It has been suggested that vascular
endothelial growth factor (VEGF) may play a causative role
in the development of ROP,7 and it is known that VEGF is
important in physiological growth of retinal vessels. However,
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mosome 6p12. Many polymorphisms of the VEGF gene have
been described, although most are relatively rare. Single
nucleotide polymorphisms (SNPs) in the VEGF 50 or 30 untrans-
lated region (UTR) have been reported to be associated with
ROP in different populations. A common polymorphism,
VEGF-634G/C (rs 2010963, previously denoted +405G/C,
position relative to transcription start site) is located in the
50 UTR.9 Two studies have found association of VEGF-
634G/C polymorphism with ROP risk10,11 but other studies
show no association between VEGF-634G/C polymorphism
and risk of ROP.12–15 These studies revealed an inconsistent
conclusion, probably due to the relatively small size of
subjects, since individual studies are usually underpowered
in detecting the effect of low penetrance genes; therefore,
in this study we conducted a meta-analysis to investigate
the association between VEGF-634G/C polymorphism and
the risk for ROP.Materials and methods
Identification and eligibility of relevant studies
To identify all articles that examined the association of
VEGF-634G/C polymorphism with ROP, we conducted a lit-
erature search in the PubMed, EMBASE, Cochrane Library,
Google, dogpile and CBM database, up to December 2013
using the following terms and keywords: ‘‘VEGF’’, ‘‘vascular
endothelial growth factor’’, ‘‘-634G/C polymorphism’’ ‘‘rs
2010963’’ and ‘‘retinopathy of prematurity’’. Additional stud-
ies were identified by a manual search from other sources
(e.g., Web of Knowledge), references of original studies or
review articles on this topic.
Inclusion and exclusion criteria
To minimize heterogeneity and facilitate the interpretation
of our results, studies included in the current meta-analysis
had to meet all the following criteria: (1) evaluation of the
VEGF-634G/C and ROP risk, (2) use of a case-control design,
(3) recruitment of confirmed ROP patients and disease-free
controls, (4) have an available genotype frequency, and (5)
an unrelated case-control study, if studies had partly over-
lapped subjects, only the one with a larger sample size was
selected, (6) sufficient published data for estimating an odds
ratio (OR) with 95% confidence interval (CI), (7) papers pub-
lished in english and (8) all the studies included were accord-
ing to tenets of the Declaration of Helsinki. The major reasons
for exclusion of studies were (1) overlapping data and (2)
case-only studies, (3) all three genotype frequency missing,
(4) family based studies, and (5) review articles.
Data extraction
Four investigators independently assessed the articles for
inclusion/exclusion and extracted data, and reached a consen-
sus on all of the items. For each study, the following informa-
tion was extracted: name of the first author; publication year;
ethnicity (country); sample size (numbers of cases and con-
trols); types of disease; sources of samples; genotyping meth-
ods; and the minor allele frequency in the controls with the
Hardy–Weinberg Equilibrium (HWE) p-value, respectively.Statistical analysis
The association between VEGF-634G/C polymorphism
and ROP was estimated by calculating pooled ORs and
95% CIs. The significance of the pooled OR was determined
by Z test (p < 0.05 was considered statistically significant).
The risk of VEGF-634G/C CC genotype on retinopathy of
prematurity was evaluated by comparing with their reference
wild type homozygote and then evaluated the risks of
(GC + CC vs. GG) and (GG + GC vs. CC) on retinopathy of
prematurity, assuming dominant and recessive effects of
the variant C allele, respectively. A random-effects or fixed-
effects model was used to calculate pooled effect estimates
in the presence (p < 0.10) or absence (p > 0.10) of heteroge-
neity. Publication bias was tested for the overall pooled anal-
ysis of VEGF-634G/C CC genotypes, dominant and recessive
model. Additionally, Begg’s funnel plot was drawn. Asymme-
try of the funnel plot means a potential publication bias.
Hardy Weinberg Equilibrium was calculated by chi-square
(w2) test. All meta-analysis tests were performed through
comprehensive meta-analysis version 2.0.16
Results
Ten studies were preliminarily retrieved. Two studies were
excluded after reading the titles and abstracts. According to
inclusion and exclusion standards, six studies were finally
included,10–15the publication years of the literatures were
between 2004 and 2013. The general features of the included
studies are shown in Table 1.
Potential publication bias and sensitivity analysis
The influence of CC genotype at -634G/C locus on ROP
was taken as the analysis index and inverted funnel plot
was drawn. Due to the small amount of the included research
and unobvious distribution trends, the inverted funnel plot
showed trend symmetry, indicating that the publication bias
was not big (Fig. 1).
Meta-analysis database
In an attempt to obtain a common estimate of the VEGF-
634G/C polymorphism effect on risk for ROP and provide
compelling evidence for association, we performed a meta-
analysis combining all available genotype and allele fre-
quency data from six published studies. The detailed charac-
teristics of each study included in the meta-analysis are
presented in Table 1, and the VEGF-634G/C polymorphism
genotype distributions from each study are presented in
Table 2. By pooling all the studies, VEGF-634G/C polymor-
phism was not associated with ROP risk (Fig. 2). In subgroup
analysis, we found that VEGF polymorphism was not signifi-
cantly correlated with increased ROP risk at allele level
(Fig. 3). When stratified by dominant and recessive models,
no association was found between VEGF-634G/C polymor-
phism and risk of ROP in all models by pooling all six studies
(Figs. 4 and 5). We also examined the association between
VEGF-634G/C polymorphism and ROP risk at ethnicity level;
the overall result showed that VEGF-634G/C polymorphism
was not associated with ROP risk in Caucasians and Asians
(Fig. 6).
Table 1. Characteristics of studies included in the VEGF-634G/C meta-analysis.
S no. Study Year Country Ethnicity Genotyping method Cases Controls p-Value HWE References
1 Cooke et al.10 2004 United Kingdom Caucasian PCR, SSCP, RFLP 91 97 0.03 0.202 PMID: 15161830
2 Vannay et al.11 2005 Hungary Caucasian Real-time PCR 86 115 0.007 0.212 PMID: 15635051
3 Shastry et al.12 2007 USA Caucasian PCR-RFLP, Sequencing 61 61 0.89 0.797 PMID: 17119993
4 Kwinta et al.13 2008 America Caucasian PCR-RFLP 60 101 0.41 0.266 PMID: 18546007
5 Kaya et al.14 2013 Turkey Asian PCR-RFLP 42 31 0.77 0.144 PMID: 23094709
6 Kalmeh et al.15 2013 Iran Asian PCR-RFLP 15 66 0.88 0.854 PMID: 23644986
HWE = Hardy–Weinberg Equilibrium.
Figure 1. Funnel plots showed symmetric distribution. Log OR is plotted against the standard error of log OR for studies on VEGF-634G/C.
Table 2. VEGF-634G/C polymorphism genotype distribution of each study included in the meta-analysis.
Author/year Genotype frequency Allele frequency Dominant model Recessive model
Cases Controls Cases Controls Cases Controls Cases Controls
GG GC CC GG GC CC G C G C GG GC + CC GG GC + CC CC GG + GC CC GG + GC
Cooke et al.10 44 39 8 31 53 13 127 55 115 79 44 47 31 66 8 83 13 84
Vannay A et al.11 30 41 15 55 53 7 101 71 163 67 30 56 55 60 15 71 7 108
Shastry et al.12 27 27 7 28 26 7 81 41 82 40 27 34 28 33 7 54 7 54
Kwinta et al.13 32 18 10 55 36 10 82 38 146 56 32 28 32 46 10 50 10 91
Kaya et al.14 25 11 6 20 8 3 61 23 48 14 25 17 20 11 6 36 3 28
Kalmeh et al.15 6 6 3 24 31 11 18 12 79 53 6 9 24 42 3 12 11 55
Figure 2. Forest plots of the association between VEGF-634G/C (co-dominant model; GG vs. CC) polymorphism and ROP risk. The squares and
horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond
represents the pooled OR and its 95% CI.
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Figure 3. Meta-analysis under allelic model (G vs. C) for the association between ROP risk and the VEGF-634G/C polymorphism.
Figure 4. Meta-analysis under dominant model (GC + CC vs GG) for the association between ROP risk and the VEGF-634G/C polymorphism.
Figure 5. Meta-analysis under recessive model (GG + GC vs. CC) for the association between ROP risk and the VEGF-634G/C polymorphism.
Figure 6. Meta-analysis under ethnicity level for the association between ROP risk and the VEGF-634G/C polymorphism.
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In the present study, we systemically reviewed all available
published studies and performed a meta-analysis to examine
the association between the VEGF-634G/C polymorphismand susceptibility to ROP. This is the first study where we
have examined all the possible models (co-dominant, domi-
nant, recessive and allele level models) to validate our results.
The association of VEGF-634G/C polymorphism with ROP
risk was also assessed at ethnicity level. Our meta-analysis
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ated with ROP risk. These results are in agreement with the
independent reports12,15 but in direct contradiction to the
previously published data10,11 in which a significant differ-
ence in the G/G genotype has been reported. By pooling
all the studies, we did not find an association between
VEGF-634G/C polymorphism and ROP, suggesting that pre-
vious controversial data may be due to small size of
population.
The deviation most likely indicates a genotyping assay
problem with an erroneous gain/loss of homozygous geno-
types. The commonly used polymerase chain reaction-restric-
tion fragment length polymorphism analysis for genotyping is
reported to have poor accuracy and reproducibility17 and
may underlie this finding. Conversely, effects of sample selec-
tion and differences in biological and environmental com-
plexity between samples could also hinder efforts to
replicate association in most of the studies which are statisti-
cally underpowered. The meta-analysis helps researchers to
deal with the diversity of the published data but in general
cannot do justice to complex human diseases, which involve
multiple genetic and environmental determinants.18 How-
ever, in the total combined data, no evidence for association
between the VEGF-634G/C polymorphism and risk of ROP
was observed. Therefore, the different results across studies
may result from small sample size and/or genotyping tech-
nique rather than ethnic differences. Since the studies
included were very limited, it is necessary to validate the
association between VEGF-634G/C polymorphism and ROP
risk in future studies. A well-designed meta-analysis can pro-
vide valuable information for researchers, policymakers, and
clinicians.
In conclusion, the present meta-analysis suggested that
VEGF-634G/C polymorphism may not be associated with risk
for ROP. More epidemiologic studies are suggested to further
ascertain the relationship between VEGF-634G/C polymor-
phism and genetic predisposition to ROP.Conflict of interest
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